Bayer | Respiratory | Strategy and Drivers | 2024
The Company Franchise Analysis (CFA) provides a comprehensive evaluation of the franchise, including benchmarking, strategic insights, and an overview of marketed products. It highlights key market drivers and offers a detailed pipeline and sales analysis, along with information on deals and significant events. This profile aims to deliver a thorough understanding of the market dynamics and the strategic positioning of the franchise’s drugs.
Related Market Assessment Reports
Report
Chronic Obstructive Pulmonary Disease – Geographic Focus: China – COPD – China In-Depth (China)
COPD is a progressive respiratory condition that primarily affects adults, particularly smokers and individuals exposed to environmental pollutants. The COPD therapeutics market in China includes a…
Report
Chronic Obstructive Pulmonary Disease – Access & Reimbursement – Access & Reimbursement – Chronic Obstructive Pulmonary Disease (US)
The dynamics within the LAMA, LABA/LAMA, LABA/ICS FDC, and LABA/LAMA/ICS FDC drug classes will continue to shape the U.S. COPD market, as will the market entry of Verona’s nebulized PDE-3/PDE-4…
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease | US/EU
The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, LABA/LAMA/ICSs, and, most recently, the…
